INTRODUCTION

Osteoporosis is considered a public health problem worldwide, with increased prevalence as the population ages. The prevalence of osteoporosis in postmenopausal women in Brazil varies from 15% to 33%. Vertebral compression fractures (VCF) are the most common fracture in osteoporotic patients, followed by hip, wrist or ankle fractures, which are a common initial presentation of osteoporosis. The majority of diagnosed vertebral fractures are due to low energy traumas, related instead to osteoporosis. Specific pathologies and severe trauma account for only 3% and 14%, respectively, of all clinically evident vertebral fractures in the community.

The prevalence of vertebral fractures in subjects aged 50 to 80 years varies from 7% to 19% in women, and from 4% to 17% in men, according to radiological studies. After suffering the first vertebral fracture, the risk of developing new vertebral fractures increases by 5 to 10 times. Although most VCF heal within a few months with conservative therapy, a significant number fail to improve, and require long-term care or surgical intervention. Fractures that fail to improve with conservative therapy are often treated with vertebral augmentation procedures (VAP).

EFFECTIVENESS OF VERTEBRAL AUGMENTATION PROCEDURES

The majority of VAP are performed for symptomatic osteoporotic or cancer-related VCF. The primary clinical goals of augmentation are to reduce the pain and disability and enhance the patient’s quality of life. It has proven success rates ranging from 80% to 95% for osteoporotic fractures, and from 70% to 92% for neoplastic fractures. Following a VAP for vertebral compression fracture, a mean reduction of 5.68 (±1.24) points is observed in the Visual Analogic Scale of Pain (VAS, from 8.36 (±0.78) to 2.86 (±1.09)), as demonstrated in a meta-analysis of 60 studies published by Eck et al.

VAP refers to vertebroplasty and/or kyphoplasty. Vertebroplasty is a minimally invasive, image-guided procedure that involves injection of cement (typically PMMA) into a fractured vertebral body. Kyphoplasty involves the initial inflation of a balloon tamp that creates a low resistance cavity within the vertebral body, into which cement is subsequently injected.
Vertebral augmentation is an established and safe procedure. Cumulative evidence demonstrates that VAP provides better outcomes than nonsurgical management in randomized clinical trials and meta-analyses. Several large retrospective studies using claims data, investigating vertebroplasty, kyphoplasty and nonsurgical management, provide additional evidence. Two blinded randomized controlled trials failed to demonstrate an advantage in their respective study populations for vertebroplasty over a placebo intervention (sham procedure) for pain reduction or improvement in disability. Following the publication of these results in 2009, the use of VAP in the USA reduced significantly. However, it is argued that those two trials suffered from significant flaws, including atypically broad inclusion criteria, allowance of chronic fractures, small sample size, and high crossover, all of which preclude definitive conclusions. For example, in the INVEST Trial, higher crossover in the sham group compared with vertebroplasty (51% versus 13%) at 3 months suggest that any short-term effects of the sham intervention are not long-lasting.

Regarding metastasis, the Cancer Patient Fracture Evaluation study prospectively enrolled patients randomized to treatment by kyphoplasty (n = 70) or non-surgical management (n = 64). The inclusion criteria included a known diagnosis of cancer, one to three VCFs, a score of more than 4 on the numerical rating scale (NRS) for pain, and a Roland–Morris Disability Questionnaire (RDQ) score of more than 10. Patients with a primary bone tumor, plasmacytoma, or a lesion deemed unsuitable for treatment with kyphoplasty were excluded. A total of 117 patients (kyphoplasty, n = 65; nonsurgical treatment, n = 52) completed the assigned treatment and had at least 1 month of follow-up. Thirty-seven patients (71%) crossed over to the kyphoplasty group after 1 month. All the outcome measurements favored the kyphoplasty and crossover groups at all time points, but the statistical significance vanished with time, perhaps because of the relatively few remaining patients in the nonsurgical management group.

COST-EFFECTIVENESS OF VERTEBRAL AUGMENTATION PROCEDURES

Borgström et al. recently published a systematic review of the literature in which they identified 5 health economic analyzes evaluating VAPs. As pointed out by the authors, the studies differed widely in terms of study design, modeling framework, and data used. Thus, a meta-analysis could not be performed. Of the five studies reviewed, three showed that VAP is cost-effective when compared with nonsurgical management. If a benefit in mortality reduction were taken into consideration in the analyses, the cost-effectiveness of vertebral augmentation would be even higher. The authors concluded that the currently available evidence from health economic analyses indicate that VAPs are cost effective when compared with nonsurgical management for VCF refractory to initial conservative treatment. No definitive conclusion could be reached regarding the cost effectiveness of vertebroplasty compared to kyphoplasty.

VERTEBROPLASTY VERSUS KYPHOPLASTY

There is discussion in the literature regarding the effectiveness of kyphoplasty over vertebroplasty and the selection of patients for one or other procedure. In summary, the available evidence demonstrates that they are safe procedures and have similar effectiveness. Evidence from some meta-analyses suggests that while both procedures have a low complication rate, kyphoplasty may have a lower rate of serious and symptomatic complications. In a recent meta-analysis of randomized and non-randomized clinical trials, concluded that both procedures are safe and effective. The also suggest that kyphoplasty could be superior to vertebroplasty in patients with large kyphosis angles, vertebral fissures, fractures in the posterior edge of the vertebral body, or significant height loss in the fractured vertebrae.

More recently, Dohrn et al. published the results of a RCT with a two-year follow-up. Both treatments provided similar sustained improvement from the baseline in terms of pain, disability, and quality of life, with the improvement lasting 2 years. Similar rates of new fractures were observed between the group in the 1- and 2-year follow-up. Surgical and hospitalization times were shorter with vertebroplasty. Kyphoplasty had fewer cement leakages, a trend of longer fracture-free survival, and less loss of kyphotic-deformity correction during the 2-year follow-up.

However, it is currently unclear in which patients these advantages of kyphoplasty over vertebroplasty outweigh its drawbacks, such as higher invasiveness, more extensive anesthesia, and higher costs. The relationship between vertebral height restoration and clinical outcome has not been established. Also, a follow-up of height loss after VAP demonstrated the loss to be greater in kyphoplasty, due to homogeneous distribution of cement, than in vertebroplasty. Therefore, height recovery differences tend to vanish with time. Specifically in cancer-related fractures, Schroeder et al. reviewed the literature regarding the safety and efficacy of both techniques, and found similar results. In a pooled analysis of published case series in patients with multiple myeloma, Khan et al. found similar clinical results comparing vertebroplasty and kyphoplasty.

INDICATIONS AND CONTRA-INDICATIONS

More than 95% of indications for VAP are related to symptomatic osteoporotic VCF refractory to medical therapy or with unacceptable medical therapy side effects, vertebral bodies weakened by neoplasm, and symptomatic vertebral body microfractures, as documented by magnetic resonance image (MRI) or nuclear imaging, and/or lytic lesions identified on computed tomography (CT), without obvious loss of vertebral body height. Other indications include enhancement of fixation in osteoporotic or cancer patients and vertebral hemangiomas. There are also some reports on VAP in the treatment of burst fractures and painful Scheuermann’s disease. Absolute contraindications include active infection, whether locally or systemically, uncorrected coagulopathy, and allergy to bone cement or opacification agent. Current use of platelet-inhibiting agents also increases the risk of bleeding, but it has been considered a relative contraindication, and, if anticoagulants or platelet inhibiting agents cannot be discontinued, it is still possible to perform vertebroplasty in the face of a pressing clinical indication. Age should not be considered a contraindication. Although severe body compression was a relative contraindication in the past, results of recent studies have shown that patients with vertebral plana can also benefit from VAP.

Involvement of the posterior vertebral body wall has been considered a relative contraindication to VAP in osteoporotic VCF. Recently, some authors have demonstrated good clinical results and low complication rates using VAP in these patients. For example, Nakano et al. compared the clinical and radiological results of 40 patients with osteoporotic burst fractures submitted to vertebroplasty with 40 historical controls submitted to medical treatment. The existence of posterior wall defects of the fractured vertebral body was determined by CT and MRI. Better clinical and radiological results were observed in the surgical group compared with non-operative treatment. In addition, the authors observed a low rate of cement leakage (10%), and no neurologic deficit, cement embolism or infection. Oncological patients with symptomatic spinal cord compression secondary to a VCF should firstly be decompressed and stabilized. Patients with asymptomatic encroachment on the spinal cord are at increased risk of adverse events in the case of significant cement leakage, but can usually still be successfully treated by VAP. These patients should be operated under neuromonitoring or local anesthesia with an anterior delivery of cement, similarly to those with upper thoracic or cervical spine fractures. Recently, Sun et al. reviewed the results of vertebroplasty for painful spinal metastasis in 43 patients with epidural encroachment in whom open surgery was not available due to poor general medical status and limited life expectancy. In this series,
32% presented signs of cord or cauda equina compression preoperatively. On post-procedural CT images, the percentage of lesion filling with bone cement was more than 50% in all levels. In spite of cement leakage being observed in 69% of patients, no deterioration of spinal cord or cauda equina compression symptoms was observed in any patients.\textsuperscript{45}

CEMENT

PMMA is the most common used in VAP.\textsuperscript{47} Several inherent advantages, including bio-inertness, ease of handling, good biomechanical strength, and cost-effectiveness, make PMMA an ideal choice for bone cement. PMMA is a low-viscosity acrylic bone cement to which a radio-opaque substance such as barium, tanta-
lium or tungsten sulphate has been added to facilitate visualization during the procedure. It is prepared by mixing a liquid component containing the monomer, accelerator and inhibitor with a powder component containing the polymer, radio-opacifier and initiator.

Recently, new biological materials have been introduced as alter-
natives to PMMA, such as calcium phosphate and hydroxyapatite. These are not exothermic, allowing the deposition of new bone that could eventually replace the cement. Nevertheless, biological cements are still expensive, and their manipulation is not easy, due to their high viscosity that hinders interstitial diffusion inside the vertebral body.\textsuperscript{42} These materials have been recommended in high-energy fractures in young patients,\textsuperscript{37} although other authors find a high rate of mechanical failure with these materials, due to their lower resistance to shear, flexion and distraction forces.\textsuperscript{43}

Theoretical mechanisms involved in pain relief after VAP have been proposed as being related to vertebral body stabilization of micro-movements and prevention of progressive vertebral collapse. In this sense, it is reasonable to think that the more cement safely injected, the better results in terms of stability and pain relief. Other theories proposed in the past, such as thermal necrosis of the surrounding tissues and nerve ends, and chemical toxicity of the PMMA, have been put in doubt in recent studies.\textsuperscript{44} There is still debate in the literature regarding the volume needed in VAP.

Some biomechanical studies have demonstrated that a minimal cement volume or cemented vertebral body volume fraction is required to restore the mechanical properties of the fractured vertebra.\textsuperscript{45} Liebschner et al.\textsuperscript{46} suggest that filling as little as 14% of vertebral body, or 3.5 mL, is sufficient to restore vertebral stiffness. Early clinical studies that attempted to verify the relationship between volume of cement and clinical outcome failed to identify a relationship between volume of injected cement and pain relief.\textsuperscript{51}

Jin et al.\textsuperscript{52} first identified a possible relationship between increase in volume fraction and clinical outcome. More recently, in the study of Nieuwenhuijse et al.\textsuperscript{49} a total of 106 patients with 196 treated vertebral compression fractures were followed up in relation to back pain and occurrence of new vertebral compression fractures in the first year. The authors classified patients as responders (average postoperative back pain ≤ 6) and nonresponders (average postoperative back pain > 6). The cemented fraction of the vertebral body was determined using volumetric analysis of the postoperative CT scan of the treated levels. The mean intravertebral cement volume was 3.94 mL (range 0.13 – 10.8 mL). The mean cemented vertebral body fraction was significantly lower in nonresponders (15% versus 21%, P = 0.002). A vertebral body fraction of 24% was identified to be the optimal fraction to be cemented. This fraction corresponded to 93% to 100% specificity for achieving pain relief, without being significantly associated with a higher risk of occurrence of cement leakage or new vertebral compression fractures.\textsuperscript{49}

Finally, Roder et al.\textsuperscript{50} found that the most important modifiable predictor for pain relief was cement volume, with a dose-dependent reduction in pain. In their study, volumes higher than 4.5 mL were associated with better clinical results.\textsuperscript{50} Other recent studies report that cement volume is of the utmost importance for correcting deformities and maintaining vertebral height.\textsuperscript{51}

Sun et al.\textsuperscript{40} recently published their experience with 43 patients with spinal metastasis and epidural compression treated with percutaneous vertebroplasty. In this report, they state that the stopping point is determined when the cement reaches the posterior quarter of the vertebral body. Also, the injection should be immediately terminated if the patient, under local anesthesia, complains of any pain, such as radicular pain, which could be due to pressure on the posterior neurological structures.

BILATERAL VERSUS UNILATERAL APPROACH

Traditionally, VAP has been performed by bilateral pedicular approaches.\textsuperscript{52} More recently, unilateral transpedicular approach have been increasingly used by spine surgeons and interventional radiologists.\textsuperscript{53} Also, a unilateral extra-pedicullar approach has been described in the literature with good results.\textsuperscript{39} The unilateral transpedicular approach has been proposed in order to reduce operative time, costs, radiation exposure and risk of medial pedicular violations.\textsuperscript{54} Another theoretical benefit of the unilateral approach is that it reduces the possibility of cement leakage through the ca-
nula tract, which could cause nerve injury.\textsuperscript{53} Biomechanical studies suggest that vertebroplasty via unipedicular approach provides comparable restoration of vertebral body stiffness when compared with a bilateral approach.\textsuperscript{55}

The unilateral approach has been advocated, particularly in patients with malignant vertebral fractures, in whom pain relief is the main goal of the procedure and multiple levels are usually performed, with the objective of reducing operative time and radiation exposure.\textsuperscript{56} As proposed by Papanastassiou et al.,\textsuperscript{56} a preoperative planning with MRI would help to determine the feasibility of unipedicular approach: a transpedicular trajectory should reach the midline at the middle or anterior third of the vertebral body without violating the medial wall of pedicle. However, in case of unsatisfactory filling (cement not crossing the midline), bilateral canulation could be performed.\textsuperscript{57}

Several clinical studies have been published addressing the unipedicular versus bipedicular approach in VAP. Yang et al.\textsuperscript{58} analyzed 4 low quality RCT with a total of 159 patients, and found no difference between unilateral and bilateral transpedicular kyphoplasty in terms of pain relief, whether in the short-term or long-term follow-up, rate of adjacent vertebral fracture, cement leakage, or loss of vertebral height in long-term follow-up. Ope-
eration time and volume of cement were significantly lower in the unipedicular kyphoplasty group.\textsuperscript{58} More recently, Huang et al.\textsuperscript{59} published a meta-analysis of 5 low quality RCT. The authors also found no differences between the two approaches, in regard to clinical outcomes, complications such as cement leakage and adjacent vertebral fractures, kyphosis angle reduction, or anterior vertebral height restoration. Again, they observed lower surgical time in the group of unilateral approach (minimum difference of 24.98 minutes; P = 0.0001).

More recently, Zhang et al.\textsuperscript{60} published the results of their small RCT comparing unilateral (n = 36) versus bilateral (n = 32) percutaneous vertebroplasty in the treatment of acute VCF. They found that cement leakage occurred in 52.7% of patients who received unilateral puncture versus 28.1% in the bilateral group (P < 0.05). No adverse events were observed. No difference in pain and quality of life was observed at 1-week follow-up. How-
ever, the authors identified statistically significant differences in pain and quality of life at 3, 6 and 12 months of follow-up, with better results in the bilateral approach group. It is important to note that these statistically significant differences are not clinically significant. Conversely, in another recent small RCT, Chen et al.\textsuperscript{61} found 39% of cement leakage in the unilateral group, versus 71% in bilateral group (P = 0.032); all patients were asymptomatic. In their study, no differences in clinical outcomes were observed at 2 weeks and 2 years. The unilateral group had less operative time (31.12 X 52.34 minutes; P < 0.001) and less amount of cement injected (3.17 X 4.36 mL; P < 0.001).
IMPOR TANCE OF IMAGING EXAMS

Magnetic resonance image (MRI) is essential in the preoperative evaluation of patient with suspected osteoporotic or malignant vertebral fracture. It can accurately confirm the presence and location of acute or subacute nonhealed vertebral fractures, assess the morphology, and rule out the existence of concomitant disease that may preclude VAP. Additionally, radiographically occult vertebral fractures may be detected on MRI, helping to avoid incomplete therapy. CT is helpful in identifying the potential route of cement extravasations by demonstrating any open fracture lines and osseous destruction, especially in pathologic fractures. Some features of the MRI demonstrate the acute or subacute nature of vertebral fractures in addition to anatomical vertebral collapse. Due to the presence of bone marrow edema, acute, subacute, or non-healing vertebral fracture appear with a hypointense signal on T1-weighted images, hyper or heterogeneous intensity on T2-weighted images, and hyper-intensity on fat-suppressed T2-weighted images or on short T1 inversion recovery (STIR) sequences where fluid represents narrow edema. However, it is also known that some patients without bone edema on MRI can also benefit from VAP. For patients with multiple fractures who are unable to submit to MRI, correlation of the CT with a bone scan may be helpful in selecting the vertebral segments that are more likely to respond to augmentation procedures. For patients who do not show a response to VAP with significantly decreased pain, or experience early relapse of similar pain, additional or repeat imaging evaluation should be performed to determine the cause of treatment failure. It is important to be aware of the expected imaging changes in previously augmented vertebrae. Persistent edema and interval height loss after a successful vertebral augmentation should not be interpreted as sufficient evidence of ongoing abnormality at the treated vertebral level. To make an accurate diagnosis, it is of vital importance to apply the knowledge of expected imaging changes in treated vertebrae, and correlate post-vertebral augmentation imaging findings with new clinical symptoms and the physical examination. Changes in the MRI after augmentation procedures can be categorized as: (1) signal changes from cement material, such as low signal intensity on T1-weighted and T2-weighted sequences; (2) signal changes in bone marrow surrounding the cement material, which are represented by gradual reduction in edema; and (3) vertebral size and morphology changes resulting from the injection of the cement. IMPORTANCE OF ROUTINE BIOPSY

The most common causes of vertebral fractures are osteoporosis or malignancy. Often, malignant fracture can mimic an osteoporotic compression fracture in radiographic image exams. Meanwhile, patients with known malignancy can present with osteoporotic fractures. In fact, diagnosing a malignant fracture in a patient without cancer history can be difficult. For these reasons, some authors advocate that biopsy should be routinely performed, as this does not add significant morbidity or operative time to the procedure. Recently, Mukhtaree et al. demonstrated their experience of routine biopsy in vertebroplasty, and observed that 4.7% of patients with absence of malignant features in clinical and radiological assessments were found to have malignant vertebral compression fracture. The also found that 10% of oncological patients in complete remission were found to have active malignant disease on biopsy. Other studies observed incidences ranging from 0.4% to 6% in routine biopsy during vertebral augmentation procedures. COMPLICATIONS OF VERTEBRAL AUGMENTATION PROCEDURES

Less than 1% of patients treated for compression fractures secondary to osteoporosis, and less than 5% of patients treated who have neoplastic involvement, suffer major complications. Perivertebral cement leakage is a common occurrence, and can be observed in the CT in as many as 88% of cases. The majority of cases are asymptomatic, and late cement migration to the lungs is rare. As a result, routine post-procedural chest CT is unnecessary in majority of cases. Cement extravasation into the spinal canal or neuroforamen is rare (0.4% to 4%) and often asymptomatic or transient, but it is important to recognize when this occurs, as it may result in painful radiculopathy and weakness. If high enough to affect the spinal cord or conus medullaris, it can even cause paraparesis, which is an emergency and requires surgical decompression.

Less frequent complications include allergic or idiosyncratic reaction, significant hemorrhage or vascular injury, symptomatic hemotherorax or pneumothorac, infection, and death. In the study of Abdelrahman et al., the infection rate after VAP was 0.46%. One major concern after a VAP is the risk of subsequent fracture. The incidence of VCFs following a VAP ranges from with an incidence of 11% to 52%. Some authors believe these subsequent fractures are a consequence of the increased stiffness of the treated vertebra, related to the amount of injected cement or, alternately, to cement leakage in the adjacent vertebral disk space. However, it is more likely that these subsequent fractures are related to the natural history of osteoporosis than to the VAP. In fact, in a recent meta-analysis of the literature, Song et al. found no differences in the incidence of secondary fractures in patients who underwent VAP and patients who underwent conservative treatment for osteoporotic VCF.

Sun et al. retrospectively studied the risk factors of subsequent fracture in a cohort of patients who underwent first-time, single-level vertebroplasty. Of 175 patients, 37 (21.1%) developed subsequent fractures requiring VAP within 12 months of the first procedure. The mean time to subsequent fracture was 85.5 days, and 81% of them developed within 6 months of the procedures. Identified risk factors for subsequent symptomatic vertebral fracture were low bone mineral density (BMD) and location of treated level at the thoracolumbar junction. The average BMD T-score was -3.4 ± 1.5 in patients with subsequent fractures and -2.9 ± 1.6 in patients without subsequent fractures. The percentage of subsequent fractures was 13.9% (10 of 72) for treated vertebrae located in the non-thoracolumbar junction, and 26.2% (27 of 103) for those located in the thoracolumbar junction. Ma et al. in a systematic review of the literature identified that risk factors include lower BMD, lower body mass index, intrascleral cement leakage, and vertebral height restoration, number of pre-existing vertebral fractures, thoracolumbar junction in initial VCFs, cement distraction, older age, and number of treated vertebrae. FINAL CONSIDERATIONS

VAPs are safe and effective in pain relief in patients with osteoporotic and tumor-associated VCFs refractory to medical treatment. Economic analyses of healthcare have shown that these procedures are cost-effective compared to nonsurgical treatment. The best existing evidence does not support clinical superiority of kyphoplasty over vertebroplasty for osteoporotic or tumor-associated VCF. PMMA is currently the cement of choice for the treatment of osteoporotic and cancer-related VCF. The volume of injected cement is a subject of debate in the literature; however it seems reasonable to consider attempting to achieve maximum filling in a safe manner (maximum of 10mL), taking care to prevent leakage of cement. The literature demonstrates that in the majority of the cases, good filling of the vertebral body can be achieved with the unilateral pedicular approach. Biopsy should be routinely performed in patients undergoing VAP for VCF. ACKNOWLEDGMENT

AO Spine Latin America. All authors declare no potential conflict of interest concerning this article.
REFERENCES


CONTROVERSIES ON VERTEBROPLASTY AND KYPHOPLASTY FOR VERTEBRAL COMPRESSION FRACTURES